Product Information
ORLISTAT 120 MG CAPSULE is a generic product labeled by H2-Pharma LLC, priced at $6.9989 per EA under NDC 61269056590. Its NADAC has been published 146 times since Dec 20, 2023.
FDA first approved this application on Apr 23, 1999.
Strength
120 mg/1
Manufacturer
H2-Pharma LLCNDC
61269056590
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ORLISTATApproval Type
Authorized Generic (NDA)
FDA Application
NDA020766FDA Approved
4/23/1999
On Market Since
6/1/2022
Pharmacological Classes
Price Statistics
The NADAC for ORLISTAT 120 MG CAPSULE has been published 146 times since Dec 20, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.9989 per EA |
|---|---|
| All-time high | $7.0033 (Sep 16, 2026) |
| All-time low | $6.7884 (Dec 18, 2024) |
| 52-week high | $7.0033 |
| 52-week low | $6.8388 |
| Median price | $6.8816 |
| Average price | $6.8886 |
| Largest weekly change | -2.4% (May 22, 2024) |
| Weeks tracked | 146 |
| Tracking since | Dec 20, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 34% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
H2-Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
orlistat market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Intestinal Lipase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ORLISTAT 120 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ORLISTAT 120 MG CAPSULE, manufactured by H2-Pharma LLC, is $6.9989 per EA (NDC 61269056590), effective Sep 30, 2026.
How has the price of ORLISTAT 120 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ORLISTAT 120 MG CAPSULE has held within roughly two percent of its current level. It has been tracked across 146 weekly CMS publications since Dec 20, 2023.
What are the highest and lowest recorded NADAC prices for ORLISTAT 120 MG CAPSULE?
Since Dec 20, 2023, the NADAC for ORLISTAT 120 MG CAPSULE has ranged from a low of $6.7884 (Dec 18, 2024) to a high of $7.0033 (Sep 16, 2026), with a median of $6.8816 per EA.
Are there cheaper alternatives to ORLISTAT 120 MG CAPSULE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, XENICAL 120 MG CAPSULE, is $4.5979 per EA — about 34% below ORLISTAT 120 MG CAPSULE.
Who manufactures ORLISTAT 120 MG CAPSULE?
ORLISTAT 120 MG CAPSULE (NDC 61269056590) is labeled by H2-Pharma LLC, and CMS classifies it as a generic product.